Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Mol Pharm ; 21(7): 3513-3524, 2024 Jul 01.
Artículo en Inglés | MEDLINE | ID: mdl-38867453

RESUMEN

The estrogen receptor α positive (ERα+) subtype represents nearly 70% of all breast cancers (BCs), which seriously threaten women's health. Positron emission computed tomography (PET) characterizes its superiority in detecting the recurrence and metastasis of BC. In this article, an array of novel PET probes ([18F]R-1, [18F]R-2, [18F]R-3, and [18F]R-4) targeting ERα based on the tetrahydropyridinyl indole scaffold were developed. Among them, [18F]R-3 and [18F]R-4 showed good target specificity toward ERα and could distinguish MCF-7 (ERα+) and MDA-MB-231 (ERα-) tumors efficiently. Especially, [18F]R-3 could differentiate the ERα positive/negative tumors successfully with a higher tumor-to-muscle uptake ratio (T/M) than that of [18F]R-4. The radioactivity of [18F]R-3 in the MCF-7 tumor was 5.24 ± 0.84%ID/mL and its T/M ratio was 2.49 ± 0.62 at 25 min postinjection, which might be the optimal imaging time point in PET scanning. On the contrary, [18F]R-3 did not accumulate in the MDA-MB-231 tumor at all. The autoradiography analysis of [18F]R-3 on the MCF-7 tumor-bearing mice model was consistent with the PET imaging results. [18F]R-3 exhibited the pharmacokinetic property of rapid distribution and slow clearance, making it suitable for use as a diagnostic PET probe. Overall, [18F]R-3 was capable of serving as a PET radiotracer to delineate the ERα+ tumor and was worthy of further exploitation.


Asunto(s)
Neoplasias de la Mama , Receptor alfa de Estrógeno , Radioisótopos de Flúor , Tomografía de Emisión de Positrones , Radiofármacos , Animales , Humanos , Femenino , Receptor alfa de Estrógeno/metabolismo , Radioisótopos de Flúor/farmacocinética , Ratones , Tomografía de Emisión de Positrones/métodos , Neoplasias de la Mama/diagnóstico por imagen , Neoplasias de la Mama/metabolismo , Radiofármacos/farmacocinética , Células MCF-7 , Línea Celular Tumoral , Ratones Desnudos , Distribución Tisular , Ratones Endogámicos BALB C , Ensayos Antitumor por Modelo de Xenoinjerto , Diseño de Fármacos
2.
Bioorg Med Chem Lett ; 104: 129727, 2024 May 15.
Artículo en Inglés | MEDLINE | ID: mdl-38582132

RESUMEN

ß-galactosidase (ß-gal) has high activity in various malignancies, which is suitable for targeted positron emission tomography (PET) imaging. Meanwhile, ß-gal can successfully guide the formation of nanofibers, which enhances the intensity of imaging and extends the imaging time. Herein, we designed a ß-galactosidase-guided self-assembled PET imaging probe [68Ga]Nap-NOTA-1Gal. We envisage that ß-gal could recognize and cleave the target site, bringing about self-assembling to form nanofibers, thereby enhancing the PET imaging effect. The targeting specificity of [68Ga]Nap-NOTA-1Gal for detecting ß-gal activity was examined using the control probe [68Ga]Nap-NOTA-1. Micro-PET imaging showed that tumor regions of [68Ga]Nap-NOTA-1Gal were visible after injection. And the tumor uptake of [68Ga]Nap-NOTA-1Gal was higher than [68Ga]Nap-NOTA-1 at all-time points. Our results demonstrated that the [68Ga]Nap-NOTA-1Gal can be used for the purpose of a new promising PET probe for helping diagnose cancer with high levels of ß-gal activity.


Asunto(s)
Sondas Moleculares , Nanofibras , Neoplasias , beta-Galactosidasa , Humanos , beta-Galactosidasa/análisis , Línea Celular Tumoral , Radioisótopos de Galio , Neoplasias/diagnóstico por imagen , Tomografía de Emisión de Positrones/métodos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA